

Financial Results for the Third Quarter Ended December 31, 2025

TAKARA BIO INC.

February 13, 2026

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Reference]

Reference Information

- **Consolidated Financial Results (3Q)**
- **Net Sales by Category (3Q)**
- **Reagents Sales by Region (3Q)**
- **Performance by Subsidiaries (3Q)**
- **Exchange Rate (Actual)**

Consolidated Financial Results (3Q)

	FY2026 3 rd quarter	Y/Y	
		Change	Ratio
(¥m)			
Net sales	28,392	▲889	▲3.0%
Cost of sales	14,252	+1,340	+10.4%
Gross profit	14,140	▲2,229	▲13.6%
SG&A expenses	18,995	+1,152	+6.5%
Operating profit	▲4,855	▲3,381	—
Ordinary profit	▲5,092	▲3,837	—
Net income attributable to owners of parent	▲9,619	▲8,240	—

②

Net Sales by Category (3Q)

	3 rd quarter Actual	Y/Y	
		Change	Ratio
(¥m)			
Reagents	21,640	▲784	▲3.5%
Instruments	589	▲55	▲8.6%
CDMO	3,792	+296	+8.5%
Gene Therapy	2,370	▲345	▲12.7%
Total net sales	28,392	▲889	▲3.0%

③

Reagents Sales by Region (3Q)

(¥m)	3 rd quarter Actual	Y/Y		Y/Y (Exchange excluded)	
		Change	Ratio	Change	Ratio
Japan	4,447	+53	+1.2%	+53	+1.2%
U.S.	9,791	▲171	▲1.7%	+51	+0.5%
China	3,316	▲847	▲20.4%	▲768	▲18.5%
Europe	2,636	+179	+7.3%	+161	+6.6%
Korea	849	▲32	▲3.7%	+22	+2.6%
India	599	+34	+6.1%	+72	+12.9%
Total	21,640	▲784	▲3.5%	▲406	▲1.8%

4

Performance by Subsidiaries (3Q)

(¥m)	3 rd quarter Actual	
	Net sales	Operating profit
Takara Bio (Non-consolidated)	14,537	▲3,614
Takara Bio Europe (Consolidated)	3,465	▲35
Takara Biotechnology (Dalian)	2,260	▲35
Takara Biomedical (Beijing)	4,190	147
Takara Korea Biomedical	962	121
DSS Takara India	641	73
Takara Bio USA	12,123	▲1,144

5

Exchange Rate

(Unit: Yen)	FY2025 3 rd quarter	FY2026 3 rd quarter
	Actual	Actual
US dollar	151.45	148.09
Euro	164.54	165.69
Yuan	20.99	20.50
100 Won	11.19	10.50
Rupee	1.82	1.71
Pound	193.30	194.76

Forward-looking Statements

Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, decline in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

For more Information : Public & Investor Relations Department
E-mail: bio-ir@takara-bio.co.jp